Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Serina Therapeutics (SER) over the last 7 years, with Q3 2025 value amounting to -$13000.0.

  • Serina Therapeutics' Cash from Investing Activities fell 33333.33% to -$13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$64000.0, marking a year-over-year increase of 2643.68%. This contributed to the annual value of -$22000.0 for FY2024, which is 9563.49% up from last year.
  • According to the latest figures from Q3 2025, Serina Therapeutics' Cash from Investing Activities is -$13000.0, which was down 33333.33% from -$46000.0 recorded in Q2 2025.
  • Serina Therapeutics' 5-year Cash from Investing Activities high stood at $9.7 million for Q2 2023, and its period low was -$10.0 million during Q1 2023.
  • Its 4-year average for Cash from Investing Activities is $11909.1, with a median of -$13000.0 in 2025.
  • Per our database at Business Quant, Serina Therapeutics' Cash from Investing Activities skyrocketed by 1175000.0% in 2021 and then plummeted by 33333.33% in 2025.
  • Serina Therapeutics' Cash from Investing Activities (Quarter) stood at $250000.0 in 2021, then plummeted by 128.0% to -$70000.0 in 2023, then soared by 92.86% to -$5000.0 in 2024, then crashed by 160.0% to -$13000.0 in 2025.
  • Its Cash from Investing Activities stands at -$13000.0 for Q3 2025, versus -$46000.0 for Q2 2025 and -$5000.0 for Q4 2024.